Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) are recommended. They are possible treatments for adults with moderate to severe ulcerative colitis if conventional therapy hasn’t worked or isn’t suitable.
Infliximab is also recommended as a possible treatment for children or young people aged 6–17 years with severe ulcerative colitis, if conventional therapy hasn't worked or isn't suitable.
People should be able to have the treatment for at least 12 months, unless it stops working well enough. Their condition should be assessed at least every 12 months. Their doctor should discuss with them the benefits and risks of continuing or stopping treatment. If treatment is stopped and the ulcerative colitis gets worse, people should be able to start treatment again.